Immune agents target inflammation
October 1st 2009Corticosteroids remain the primary treatment for inflammatory diseases that involve the eye and orbit. However, side effects and treatment failures have provided the impetus for the use of safer and more specific immunosuppressive agents. The selection of a specific agent will depend on multiple factors. The next step in the use and development of alternative immune agents will likely involve both the identification of inflammatory conditions that are most responsive to a particular agent and identifying patient-specific factors that might predict a response to that agent.
FDA approves bepotastine for ocular itching
October 1st 2009The recent FDA approval of bepotastine besilate ophthalmic solution 1.5% (Bepreve, ISTA Pharmaceuticals) as a twice-daily prescription eye drop treatment for ocular itching associated with allergic conjunctivitis gives clinicians an additional treatment option, one with multiple mechanisms of action and a rapid onset of action.
Dr. Travis Meredith is new AUPO president
September 16th 2009Travis Meredith, MD, has been elected as the new president of the Association of University Professors of Ophthalmology (AUPO), which is composed of department chairmen, residency directors, and research directors of ophthalmology departments in the United States and Canada, according to a prepared statement.
Bausch & Lomb to consolidate its contact lens manufacturing
September 16th 2009Bausch & Lomb intends to consolidate its worldwide contact lens manufacturing and proposes to begin moving most of its global contact lens production to its existing sites in Waterford, Ireland, and Rochester, NY, according to a prepared statement. ??
Allergan, Pieris AG agreement targets anticalin for treatment of ocular disorders
September 16th 2009Pieris AG announced that it has entered into a collaboration agreement with Allergan Inc. that will combine Pieris' proprietary anticalin technology with Allergan's drug delivery and ophthalmic drug development with a goal of developing agents for the treatment of serious ocular disorders.
Ganciclovir ophthalmic gel 0.15% approved by FDA for herpetic keratitis
September 16th 2009Sirion Therapeutics Inc. announced the FDA approval of its new drug application for ganciclovir ophthalmic gel 0.15% (Zirgan) as a treatment for acute herpetic keratitis. The FDA granted orphan drug designation to the gel for this indication in April 2007.
MBA: Is this the right decision for me?
September 15th 2009Many, if not most, ophthalmologists have at least entertained the idea of obtaining a master of business administration degree. This three-part series is designed to provide guidance through the process. The first steps involve the realization of goals, the return on investment, and the application process.
San Francisco unmatched as a travel destination
September 15th 2009San Francisco is nearly synonymous with a high cost of living. The advent and financial success of the early years of the Internet revolution still lures high-income folks to the city by the bay. Property values and household income are among the top in the nation, which enables a profitable restaurant and entertainment scene.